Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Key Highlights
- ➤Eikon (EIKN) will present seven clinical abstracts at the 2026 ESMO Congress.
- ➤EIK1001 updates include TeLuRide-005 results and a Phase 2/3 NSCLC study.
- ➤EIK1003 updates cover advanced solid tumors and metastatic prostate cancer combinations.
- ➤EIK1004 initial results evaluate a CNS-penetrant PARP1 inhibitor in advanced solid tumors.
- ➤EIK1005 data include preliminary safety, tolerability, and pharmacokinetics for a WRN inhibitor.
Expert Statements
Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon
“We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs.”
Roger M. Perlmutter, Chief Executive Officer and Board Chair of Eikon
“Eikon scientists and clinicians look forward to discussing these results with the broader oncology community in Spain.”
Presentations to cover updates across Eikon’s clinical pipeline including: * Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) * Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors * Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer * Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies * Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026.
Get started
Create a free account to read the full story.